Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.
暂无分享,去创建一个
Wang Min | Ge Lou | Ming-zhu Yin | Xia Li | G. Lou | W. Min | Haifeng Zhang | W. Ji | S. Bellone | A. Santin | Xia Li | Alessandro D Santin | Stefania Bellone | Mingzhu Yin | Weidong Ji | Haifeng Zhang | Huanjiao Jenny Zhou | Shu Tan | Xiaocao Xu | Xiaocao Xu | S. Tan | H. Zhou | Mingzhu Yin | Weidong Ji
[1] G. Freeman,et al. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. , 2013, Cancer research.
[2] M. Ewen,et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. , 2011, Cancer cell.
[3] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[4] J. McGee,et al. Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids , 2015, Oncotarget.
[5] R. Agarwal,et al. Mechanisms of transcoelomic metastasis in ovarian cancer. , 2006, The Lancet. Oncology.
[6] S. Gordon,et al. Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype1 , 2006, The Journal of Immunology.
[7] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[8] L. Twiggs,et al. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary. , 2005, Gynecologic oncology.
[9] S. Fagerholm,et al. alpha-Chain phosphorylation of the human leukocyte CD11b/CD18 (Mac-1) integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation. , 2006, Blood.
[10] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[11] J. Au,et al. Intraperitoneal therapy for peritoneal cancer. , 2010, Future oncology.
[12] Yingke Xu,et al. A network of interactions enables CCM3 and STK24 to coordinate UNC13D-driven vesicle exocytosis in neutrophils. , 2013, Developmental cell.
[13] Xia Li,et al. Over‐expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer , 2011, Journal of surgical oncology.
[14] G. Coukos,et al. Deciphering and reversing tumor immune suppression. , 2013, Immunity.
[15] G. Cline,et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.
[16] M. Zucchetti,et al. Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.
[17] E. Lengyel. Ovarian cancer development and metastasis. , 2010, The American journal of pathology.
[18] A. Jimeno,et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] N. Teng,et al. FACS analysis of peritoneal lymphocytes in ovarian cancer and control patients. , 1994, Immunobiology.
[20] N. Weiss,et al. Predictive value of symptoms for early detection of ovarian cancer. , 2010, Journal of the National Cancer Institute.
[21] John Condeelis,et al. Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.
[22] E. Yordan,et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Y. Suárez,et al. Cutting Edge: TNF-Induced MicroRNAs Regulate TNF-Induced Expression of E-Selectin and Intercellular Adhesion Molecule-1 on Human Endothelial Cells: Feedback Control of Inflammation , 2009, Journal of Immunology.
[24] A. Beaudet,et al. Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. , 1996, The Journal of clinical investigation.
[25] W. Min,et al. MyD88-dependent, superoxide-initiated inflammation is necessary for flow-mediated inward remodeling of conduit arteries , 2008, The Journal of experimental medicine.
[26] R. Drapkin,et al. Combined therapy with thrombospondin‐1 type I repeats (3TSR) and chemotherapy induces regression and significandy improves survival in a preclinical model of advanced stage epithelial ovarian cancer , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] P. Carmeliet,et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. , 2011, Cancer cell.
[28] E. Lengyel,et al. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. , 2014, The American journal of pathology.
[29] P. Biberfeld,et al. MALA‐2, mouse homologue of human adhesion molecule ICAM‐1 (CD54) , 1989, European journal of immunology.
[30] C. Lewis,et al. Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.
[31] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[32] G. Mor,et al. Epithelial ovarian cancer cells secrete functional Fas ligand. , 2003, Cancer research.
[33] E. Puré,et al. Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. , 1993, Journal of immunology.
[34] S. Meri,et al. Ascitic complement system in ovarian cancer , 2005, British Journal of Cancer.
[35] R. Weinberg,et al. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis , 2014, Nature Cell Biology.
[36] S. Rafii,et al. Inflammation joins the "niche". , 2008, Cancer cell.
[37] Will Liao,et al. The cellular and molecular origin of tumor-associated macrophages , 2014, Science.
[38] Ming-zhu Yin,et al. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis , 2011, International journal of cancer.
[39] Kathleen R. Cho,et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. , 2013, Immunity.
[40] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[41] J. Massagué,et al. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. , 2011, Cancer cell.
[42] R. Jain,et al. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. , 2011, Cancer cell.
[43] A. Skubitz,et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. , 2004, Gynecologic oncology.
[44] Andrew Burgess,et al. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance , 2010, Proceedings of the National Academy of Sciences.
[45] A. Reuss,et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] S. Cherry,et al. Infection-induced type I interferons activate CD11b on B-1 cells for subsequent lymph node accumulation , 2015, Nature Communications.
[47] Prahlad T. Ram,et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. , 2014, Cancer cell.
[48] E. Ratner,et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo , 2015, Cancer.
[49] Erik Sahai,et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. , 2005, Cancer research.
[50] N. Van Rooijen,et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. , 2007, Cancer research.
[51] A. Skubitz,et al. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. , 2001, The American journal of pathology.
[52] R. Freedman,et al. Defective Antitumor Function of Monocyte-Derived Macrophages from Epithelial Ovarian Cancer Patients , 2006, Clinical Cancer Research.
[53] G. Rice,et al. α2β1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis , 2007, Journal of Carcinogenesis.
[54] Jinghang Zhang,et al. CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.
[55] J. Shih,et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. , 2006, Cancer cell.
[56] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[57] F. Takei. Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (MALA-2). , 1985, Journal of immunology.
[58] F. Takei,et al. Molecular cloning of murine intercellular adhesion molecule (ICAM‐1). , 1989, The EMBO journal.
[59] J. McGee,et al. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids. , 2016, Endocrine-related cancer.
[60] David A. Cheresh,et al. Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.